http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-003175-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94ff2d78578d95d1e8d3a2233c76188d
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D249-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
filingDate 1996-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 1998-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber AR-003175-A1
titleOfInvention A PHARMACEUTICAL COMPOSITION COMPRISING A PHARMACEUTICALLY ACCEPTABLE CARRIER AND A CHEMOTHERAPEUTICAL AGENT AND A TRIAZOL, SUCH A PHARMACEUTICAL COMPOSITION, WHICH INCLUDES A POTENTIAL, 1-POTENTIAL USE BY A CHEMICAL DRIVER, AND USE AND SAID TRIAZOLE TO TREAT CANCER, TUMORS OR VIRAL INFECTIONS IN MAMMALS OF HOT BLOOD
abstract A pharmaceutical composition for the treatment of cancers and tumors in mammals is presented, comprising 2- (2,4-difluorophenyl) -1,3-bis (1H-1,2,4-triazol-1-yl) propan-2 -ol and its derivatives. Together with 2- (2,4-difluorophenyl) -1,3-bis) 1H-1,2,4-triazol-1-yl) propan-2-ol and its derivatives, a chemotherapeutic agent can be used, as well as potentiators. . 2- (2,4-Difluorophenyl) -1,3-bis (1H-1,2,4-triazol-1-yl) propan-2-ol and its derivatives can also be used for the treatment of viral infections, either alone or in combination with other antiviral agents or with a booster.
priorityDate 1995-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419513958
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394670
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID67516
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457832278
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3365
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419505877
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID406908050
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3776

Total number of triples: 30.